Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins - PubMed (original) (raw)
Comparative Study
. 1989 Dec 25;264(36):21682-8.
Affiliations
- PMID: 2600087
Free article
Comparative Study
Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins
D W Russell et al. J Biol Chem. 1989.
Free article
Abstract
Seven imperfect repeats of a 40-amino acid cysteine-rich sequence constitute the ligand binding domain of the low density lipoprotein (LDL) receptor. To assess the contribution of each repeat, three site-directed mutations were made individually in each repeat: 1) deletion of the repeat, 2) substitution of a conserved isoleucine with aspartic acid, and 3) substitution of a conserved aspartic acid with tyrosine. cDNAs containing these mutations were transfected into simian COS cells and assayed for their ability to bind LDL, which contains a 500-kDa protein ligand (apoB-100), and beta-migrating very low density lipoprotein (beta-VLDL), which contains multiple copies of a 33-kDa ligand (apoE). The results showed that binding of the two ligands required different combinations of repeats. LDL binding required repeats 3-7; deletion of any one of these repeats markedly reduced LDL binding. In contrast, beta-migrating very low density lipoprotein binding was insensitive to the loss of any single repeat with the important exception of repeat 5, whose loss reduced binding by 60%. The same effects were obtained when each of the repeats was altered by either of the two substitution mutations. The current findings suggest that a multiplicity of cysteine-rich repeats may allow a single protein to bind several different protein ligands by employing different combinations of repeats.
Similar articles
- Mutational analysis of the ligand binding domain of the low density lipoprotein receptor.
Esser V, Limbird LE, Brown MS, Goldstein JL, Russell DW. Esser V, et al. J Biol Chem. 1988 Sep 15;263(26):13282-90. J Biol Chem. 1988. PMID: 3417658 - [Effects of induced deletion of repeats in binding domain of the VLDL receptor on its ligand-binding capacity].
Liu ZG, Qu S, Feng N, Zong YQ, Deng YZ, Feng ZC. Liu ZG, et al. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 Mar;34(2):158-64. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002. PMID: 12006989 Chinese. - Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family.
Hussain MM. Hussain MM. Front Biosci. 2001 Mar 1;6:D417-28. doi: 10.2741/hussain1. Front Biosci. 2001. PMID: 11229872 Review. - The mammalian low-density lipoprotein receptor family.
Hussain MM, Strickland DK, Bakillah A. Hussain MM, et al. Annu Rev Nutr. 1999;19:141-72. doi: 10.1146/annurev.nutr.19.1.141. Annu Rev Nutr. 1999. PMID: 10448520 Review.
Cited by
- Proteolysis of the low-density lipoprotein receptor in hepatocytes is mediated by BMP1 but not by other astacin proteases.
Kellett KAB, Fisher K, Aldworth H, Hooper NM. Kellett KAB, et al. FEBS Lett. 2023 Jun;597(11):1489-1502. doi: 10.1002/1873-3468.14667. Epub 2023 Jun 5. FEBS Lett. 2023. PMID: 37235726 Free PMC article. - CysDB: a human cysteine database based on experimental quantitative chemoproteomics.
Boatner LM, Palafox MF, Schweppe DK, Backus KM. Boatner LM, et al. Cell Chem Biol. 2023 Jun 15;30(6):683-698.e3. doi: 10.1016/j.chembiol.2023.04.004. Epub 2023 Apr 28. Cell Chem Biol. 2023. PMID: 37119813 Free PMC article. - Endocrine Regulation of Microvascular Receptor-Mediated Transcytosis and Its Therapeutic Opportunities: Insights by PCSK9-Mediated Regulation.
Mazura AD, Pietrzik CU. Mazura AD, et al. Pharmaceutics. 2023 Apr 18;15(4):1268. doi: 10.3390/pharmaceutics15041268. Pharmaceutics. 2023. PMID: 37111752 Free PMC article. Review. - Two novel variations in LRP2 cause Donnai-Barrow syndrome in a Chinese family with severe early-onset high myopia.
Yuan S, Huang X, Zhang S, Yang S, Rui X, Qi X, Wang X, Zheng Y, Rong W, Sheng X. Yuan S, et al. Front Genet. 2023 Jan 27;14:1107347. doi: 10.3389/fgene.2023.1107347. eCollection 2023. Front Genet. 2023. PMID: 36777721 Free PMC article. - Pathogenic gain-of-function mutations in the prodomain and C-terminal domain of PCSK9 inhibit LDL binding.
Sarkar SK, Matyas A, Asikhia I, Hu Z, Golder M, Beehler K, Kosenko T, Lagace TA. Sarkar SK, et al. Front Physiol. 2022 Sep 14;13:960272. doi: 10.3389/fphys.2022.960272. eCollection 2022. Front Physiol. 2022. PMID: 36187800 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous